Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate receptor ionotropic, kainate (KAR) is a member of the ionotropic glutamate receptor family, functioning as a ligand-gated cation channel primarily in the central nervous system. KARs assemble as tetramers composed of five possible subunits (GluK1–GluK5) and mediate excitatory neurotransmission upon activation by glutamate or exogenous agonists like kainic acid. KARs play a key role in both fast synaptic transmission and the modulation of synaptic plasticity, and are expressed postsynaptically as modulators of excitation and presynaptically as regulators of neurotransmitter release. Structural and functional diversity among KAR subunits enable distinct roles in neuronal development, circuit formation, and pathology. Dysregulation and altered KAR function contribute to neurological and psychiatric diseases including epilepsy, depression, schizophrenia, and neurodegenerative diseases. KARs are considered important therapeutic targets, with ongoing research into agonists, antagonists, and allosteric modulators for potential interventions.
Agonists (e.g., kainic acid, glutamate): activate the receptor and open the cation channel, resulting in depolarization and excitatory neurotransmission. Antagonists: block receptor activation by competing with agonist binding, inhibiting channel opening. Positive allosteric modulators: enhance receptor activity or prolong channel opening, often by stabilizing open or non-desensitized conformations.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic, kainate (KAR).